Federated Hermes, Inc. Black Diamond Therapeutics, Inc. Transaction History
Federated Hermes, Inc.
- $50.2 Billion
- Q2 2025
A detailed history of Federated Hermes, Inc. transactions in Black Diamond Therapeutics, Inc. stock. As of the latest transaction made, Federated Hermes, Inc. holds 291 shares of BDTX stock, worth $1,225. This represents 0.0% of its overall portfolio holdings.
Number of Shares
291Holding current value
$1,225% of portfolio
0.0%Shares
13 transactions
Others Institutions Holding BDTX
# of Institutions
98Shares Held
41.3MCall Options Held
0Put Options Held
0-
T. Rowe Price Investment Management, Inc. Baltimore, MD10.5MShares$44.3 Million0.02% of portfolio
-
Vestal Point Capital, LP New York, NY5.6MShares$23.6 Million0.73% of portfolio
-
Nea Management Company, LLC Timonium, MD4.45MShares$18.7 Million0.91% of portfolio
-
Black Rock Inc. New York, NY3.22MShares$13.5 Million0.0% of portfolio
-
Bellevue Group Ag Kuesnacht, V82.73MShares$11.5 Million0.15% of portfolio
About Black Diamond Therapeutics, Inc.
- Ticker BDTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,339,500
- Market Cap $153M
- Description
- Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epide...